DUBLIN–(BUSINESS WIRE)–The “Purinergic Receptor (Purinoceptor) Antagonists – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.
This “Purinergic Receptor (Purinoceptor) Antagonists – Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Purinergic Receptor (Purinoceptor) Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Purinergic Receptor (Purinoceptor) Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Purinergic Receptor (Purinoceptor) Antagonists.
Purinergic Receptor (Purinoceptor) Antagonists Emerging Drugs Chapters
This segment of the Purinergic Receptor (Purinoceptor) Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Purinergic Receptor (Purinoceptor) Antagonists Emerging Drugs
Gefapixant: Merck & Co
Gefapixant, an investigational, orally administered, selective Purinergic P2X3 receptor antagonist, for the treatment of refractory chronic cough (RCC) or unexplained chronic cough (UCC) in adults. In March 2021, Merck known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for gefapixant.
Selatogrel: Idorsia Pharmaceuticals
Selatogrel acts as P2Y12 receptor antagonist, it is administered subcutaneously. It is being developed by Antares Pharma in partnership with Idorsia Pharmaceuticals for the treatment of myocardial infarction using Antare’s Quickshot auto-injector. It is currently in Phase III stage of development.
Purinergic Receptor (Purinoceptor) Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Purinergic Receptor (Purinoceptor) Antagonists drugs segregated based on following parameters that define the scope of the report.
Major Players in Purinergic Receptor (Purinoceptor) Antagonists
There are approx. 40+ key companies which are developing the therapies for Purinergic Receptor (Purinoceptor) Antagonists. The companies which have their Purinergic Receptor (Purinoceptor) Antagonists drug candidates in the most advanced stage, i.e. Pre-registration include, Merck & Co.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Purinergic Receptor (Purinoceptor) Antagonists drugs.
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Purinergic Receptor (Purinoceptor) Antagonists drugs?
- How many Purinergic Receptor (Purinoceptor) Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Purinergic Receptor (Purinoceptor) Antagonists?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Purinergic Receptor (Purinoceptor) Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Purinergic Receptor (Purinoceptor) Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Incyte Corporation
- Arcus Biosciences
- Corvus Pharmaceuticals
- Idorsia Pharmaceuticals
- Tarus Therapeutics
- Dizal Pharmaceutical
- Corvus Pharmaceuticals
Key Products
- INCB-106385
- Etrumadenant
- Ciforadenant
- Selatogrel
- TT-4
- TT-10
- DZD-2269
- Ciforadenant
Key Topics Covered:
Introduction
Executive Summary
Purinergic Receptor (Purinoceptor) Antagonists: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
Selatogrel: Idorsia Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Etrumadenant: Arcus Biosciences
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I)
- Comparative Analysis
DZD-2269: Dizal Pharmaceutical
- Product Description
- Research and Development
- Product Development Activities
Preclinical stage products
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Purinergic Receptor (Purinoceptor) Antagonists Key Companies
Purinergic Receptor (Purinoceptor) Antagonists Key Products
Purinergic Receptor (Purinoceptor) Antagonists- Unmet Needs
Purinergic Receptor (Purinoceptor) Antagonists- Market Drivers and Barriers
Appendix
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/b1e0fi
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900